Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 246

Sort by

Sort Order Select

Journal Articles

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Blood (2025) 146 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2025-7092

Published: 2025

Journal Articles

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Rahul Shah, Xiaowen Sun, Lei Feng, Anath Lionel, Zachary Hunzeker, Sairah Ahmed, Jeremy Ramdial, Michelly Abreu, Karla Ow, Minifrida Santiago, Jaimole Varghese, Sherry Adkins, Misha Hawkins, Sandra Horowitz, Amy Ayers, Partow Kebriaei, Elizabeth Shpall, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 6319.

https://doi.org/10.1182/blood-2025-6319

Published: 2025

Journal Articles

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Aung Tun, Romil Patel, Frederique St-Pierre, Evguenia Bhurtel, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka Pophali, Timothy Fenske, Reem Karmali, Patrick Johnston, Sairah Ahmed

Blood (2025) 146 (Supplement 1): 6310.

https://doi.org/10.1182/blood-2025-6310

Published: 2025

Journal Articles

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Blood (2025) 146 (Supplement 1): 666.

https://doi.org/10.1182/blood-2025-666

Published: 2025

Journal Articles

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2025-4575

Published: 2025

Journal Articles

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2025-1852

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Mark Hamilton, Ajlan Al Zaki, Lei Feng, Zachary Hunzeker, Dai Chihara, Hun Lee, Chitra Hosing, Laura Ebarle, Oluwadare Ajishegiri, Jason Westin, Sairah Ahmed, Sattva Neelapu, Paolo Strati

Blood (2025) 146 (Supplement 1): 5485.

https://doi.org/10.1182/blood-2025-5485

Published: 2025

Journal Articles

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Krish Patel, Matthew Lunning, Konstantinos Sdrimas, Minoo Battiwalla, Uttam Rao, Yi Lin, Sami Ibrahimi, Jennifer L. Crombie, Sairah Ahmed, Iris Isufi, Matthew Frigault, David Bernasconi, Debasmita Roy, Marcelo Pasquini, Bradley D. Hunter

Blood (2025) 146 (Supplement 1): 5482.

https://doi.org/10.1182/blood-2025-5482

Published: 2025

Journal Articles

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Blood (2025) 146 (Supplement 1): 467.

https://doi.org/10.1182/blood-2025-467

Published: 2025

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Amanda Chron, Kelsey Baron, Ashlee Joseph, Ayushi Chauhan, Sonia Godbole, Andrew Jallouk, Amy Ayers, Ajay Major, Swetha Thiruvengadam, Narendranath Epperla, Shakthi Bhaskar, Alex Herrera, Yazeed Sawalha, Sairah Ahmed, Gilles Salles, Lorenzo Falchi, Allison Bock

Blood (2025) 146 (Supplement 1): 958.

https://doi.org/10.1182/blood-2025-958

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Sairah Ahmed, Jinwen Cao, Matthew Mei, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Mohamed Iburahim Haja Maideen, Omnia Farahat, Adam Braun, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2025-1844

Published: 2025

Journal Articles

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Blood (2025) 146 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2025-1837

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Karan Chohan, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

Blood (2025) 146 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2025-5520

Published: 2025

Journal Articles

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Blood (2025) 146 (Supplement 1): 4515.

https://doi.org/10.1182/blood-2025-4515

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma

Real world experience of anakinra for the treatment of immune effector cell-associated neurotoxicity syndrome in large B-cell lymphoma

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial

Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma

Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Consolidation with loncastuximab tesirine for large B-cell lymphoma patients in partial response after CART: Planned interim futility analysis of a phase II trial

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only